In 2023, Croatia led beta blocker sales globally with $208.3 million, followed by Canada and South Korea. Canada experienced a sales decline, whereas South Korea, Spain, and Chile showed positive growth. Sweden, Slovakia, and Denmark saw modest increases, while Finland and Costa Rica faced declines. Iceland achieved the highest growth rate. Over the past five years, the compound annual growth rate indicates a modest global average increase in beta blocker sales.
Future trends to watch include:
- Potential market expansions in Asia due to increasing healthcare spending.
- Innovations in drug delivery and personalized medicine boosting sales.
- The impact of global health policies on drug pricing and accessibility.
Top countries in Beta Blocking Medicine Sales by Country
# | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
---|---|---|---|---|---|---|
1 | 1 Croatia | 208.3 | 2023 | -1.93% | +0.34% | View data |
2 | 2 Canada | 201.4 | 2023 | -2.42% | -4.11% | View data |
3 | 3 South Korea | 182.7 | 2023 | +1.39% | +3.38% | View data |
4 | 4 Spain | 179.7 | 2023 | +2.16% | +4.14% | View data |
5 | 5 Chile | 59.9 | 2023 | +2.22% | +4.62% | View data |
6 | 6 Sweden | 52.2 | 2023 | -0.38% | +1.95% | View data |
7 | 7 Slovakia | 48.8 | 2023 | +2.52% | +2.95% | View data |
8 | 8 Denmark | 21.6 | 2023 | +0.47% | +3.04% | View data |
9 | 9 Finland | 21.1 | 2023 | -2.76% | -3.64% | View data |
10 | 10 Norway | 20.9 | 2023 | -0.48% | +1.5% | View data |